Shenzhen Hepalink Pharmaceutical Group Co Ltd (9989.HK) released a profit for its first quarter that Increased, from the same period last year
The company's earnings totaled RMB187.57 million, or RMB0.1278 per share. This compares with RMB156.59 million, or RMB0.1067 per share, last year.
The company's revenue for the period fell 4.6% to RMB1.330 billion from RMB1.394 billion last year.
Shenzhen Hepalink Pharmaceutical Group Co Ltd earnings at a glance (GAAP) :
-Earnings: RMB187.57 Mln. vs. RMB156.59 Mln. last year.-EPS: RMB0.1278 vs. RMB0.1067 last year.-Revenue: RMB1.330 Bln vs. RMB1.394 Bln last year.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.